Characteristics of a unique visual field defect attributed to vigabatrin
about
Guideline for prescribing vigabatrin in children has been revised. Vigabatrin Paediatric Advisory GroupVisual field loss associated with vigabatrin: quantification and relation to dosage.Retinal nerve fibre layer characteristics with vigabatrin-associated visual field loss--could scanning laser polarimetry aid diagnosis?Relationship between the area of isopters and Vigabatrin dosage during two years of observation.Comprehensive review of visual defects reported with topiramateCharacteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in childrenNeurotoxic effects of GABA-transaminase inhibitors in the treatment of epilepsy: ocular perfusion and visual performance.Does the Swedish Interactive Threshold Algorithm (SITA) accurately map visual field loss attributed to vigabatrin?Structural modifications of (1S,3S)-3-amino-4-difluoromethylenecyclopentanecarboxylic acid, a potent irreversible inhibitor of GABA aminotransferaseVigabatrin and visual field defects in pediatric epilepsy patients.Evaluating risks for vigabatrin treatmentReduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy.Contrast sensitivity is reduced in children with infantile spasms.Electroretinogram changes in a pediatric population with epilepsy: is vigabatrin acting alone?Treatment of refractory complex partial seizures: role of vigabatrin.Genetic variability in estrogen disposition: Potential clinical implications for neuropsychiatric disorders.Treatment options for refractory and difficult to treat seizures: focus on vigabatrinUnderstanding and interpreting vision safety issues with vigabatrin therapy.Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin.The Hospital for Sick Children, Toronto, Longitudinal ERG study of children on vigabatrin.Changes in the electroretinogram resulting from discontinuation of vigabatrin in childrenVigabatrin visual toxicity: evolution and dose dependence.The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication.Attenuation of the retinal nerve fibre layer and reduced retinal function assessed by optical coherence tomography and full-field electroretinography in patients exposed to vigabatrin medication.Management of epilepsy in tuberous sclerosis complex.Modelling the topography of absolute defects in patients exposed to the anti-epileptic drug vigabatrin and in normal subjects using automated static suprathreshold perimetry of the entire 80° visual field.Preserved visual function in a case of occipitoparietal microgyria.Retinal nerve fiber layer thickness in vigabatrin-exposed patients.
P2860
Q24524752-BA6A4EE6-3557-4509-9622-9AD8E58B9956Q32154724-44B5C0E1-7757-439C-ADDD-3F51DBFE76A1Q33280769-73F49735-26F7-4E8D-BF78-7A37140EE0A5Q33581354-1EEC4D4D-199D-432D-962B-BB77585CA2E0Q33739946-6DEE0694-DFA6-4472-9C29-17E3521B462FQ33982061-81A4AF66-3852-4A3C-8C12-00184BEEA92FQ34928181-B83E4E44-5C53-4637-A5C2-1B8078FF797FQ35336784-A6288C1F-2DF0-4B99-8012-33BB36644853Q35754132-6435CA2F-5098-48A8-B3A4-60C47F6E6B28Q37313207-C33DD7A6-DF43-445D-B417-5938A6450D6BQ37380373-6A814241-F433-419D-B409-3561FADE58E0Q37431696-6F0AC1E7-A5FD-499D-884D-00699A7DB6FCQ37431702-11A3D536-4D85-4E52-ACC0-F815DC735E63Q37431730-A3548451-A390-4504-88F9-CF7E6FBEB99AQ37620193-7DFE1E5F-3DC5-44E5-9D3D-D05A25FE3025Q37795699-AA28023F-556C-43BC-91F7-712AAEB3B7BEQ37937441-2453D50F-2777-4BF4-926B-23BDA48D1E94Q37953582-C2B51810-438E-4E3D-9BF8-5AA919059E86Q41815393-17AAEFC6-FA8F-4BBF-ACFD-5E2D9F4A8463Q41849869-17B4C7C3-F2EB-44BC-9CC1-DC8DD4C8C641Q41849881-819BB211-BDC5-4C56-B38C-007D764FB128Q43622918-C2219C97-6C26-4046-B435-108823F3492FQ44849769-A6427A4D-0FEB-4298-8289-460471C11C16Q45187625-849D458F-ECF4-423C-AE13-C88D356F440CQ46697537-13CFC190-8262-4647-B12E-62F0601D14F0Q46793492-38EFEEAE-3C05-41B4-8182-2FE382289393Q48480588-3A543FEE-C4B3-431E-8999-63DD05EB19B2Q51611825-80BD5993-D3F2-4F19-A28C-208B41B5CA37
P2860
Characteristics of a unique visual field defect attributed to vigabatrin
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Characteristics of a unique visual field defect attributed to vigabatrin
@ast
Characteristics of a unique visual field defect attributed to vigabatrin
@en
Characteristics of a unique visual field defect attributed to vigabatrin
@nl
type
label
Characteristics of a unique visual field defect attributed to vigabatrin
@ast
Characteristics of a unique visual field defect attributed to vigabatrin
@en
Characteristics of a unique visual field defect attributed to vigabatrin
@nl
prefLabel
Characteristics of a unique visual field defect attributed to vigabatrin
@ast
Characteristics of a unique visual field defect attributed to vigabatrin
@en
Characteristics of a unique visual field defect attributed to vigabatrin
@nl
P2093
P2860
P1433
P1476
Characteristics of a unique visual field defect attributed to vigabatrin
@en
P2093
C Martinez
G F Harding
G Reinshagen
P2860
P304
P356
10.1111/J.1528-1157.1999.TB01599.X
P407
P577
1999-12-01T00:00:00Z